fam-trastuzumab deruxtecan
E902880
Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
All labels observed (2)
| Label | Occurrences |
|---|---|
| fam-trastuzumab deruxtecan canonical | 3 |
| trastuzumab deruxtecan | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074264 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: fam-trastuzumab deruxtecan Context triple: [HER2 receptor, targetOfDrug, fam-trastuzumab deruxtecan]
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: fam-trastuzumab deruxtecan Target entity description: Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
HER2-targeted therapy
ⓘ
antibody–drug conjugate ⓘ anticancer drug ⓘ |
| bindsTo | human epidermal growth factor receptor 2 ⓘ |
| hasAdverseEffect |
alopecia
ⓘ
decreased appetite ⓘ fatigue ⓘ interstitial lung disease ⓘ myelosuppression ⓘ nausea ⓘ neutropenia ⓘ pneumonitis ⓘ vomiting ⓘ |
| hasBoxedWarning |
embryo-fetal toxicity
ⓘ
interstitial lung disease and pneumonitis ⓘ |
| hasBrandName | Enhertu ⓘ |
| hasComponent |
cleavable tetrapeptide-based linker
ⓘ
topoisomerase I inhibitor payload ⓘ trastuzumab-based monoclonal antibody ⓘ |
| hasDosingInterval | every 3 weeks in many regimens ⓘ |
| hasDrugClass |
HER2-directed antibody–drug conjugate
ⓘ
topoisomerase I inhibitor conjugate ⓘ |
| hasGenericName |
trastuzumab deruxtecan
ⓘ
linked to:
fam-trastuzumab deruxtecan
|
| hasIndication |
HER2-low unresectable or metastatic breast cancer
ⓘ
HER2-mutant unresectable or metastatic non-small cell lung cancer ⓘ HER2-positive gastroesophageal junction adenocarcinoma ⓘ HER2-positive solid tumors in certain settings ⓘ HER2-positive unresectable or metastatic breast cancer ⓘ HER2-positive unresectable or metastatic gastric cancer ⓘ |
| hasInternationalNonproprietaryName |
trastuzumab deruxtecan
ⓘ
linked to:
fam-trastuzumab deruxtecan
|
| hasMolecularTarget | ERBB2 ⓘ |
| hasPayload | deruxtecan ⓘ |
| hasRegulatoryApproval |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| hasTargetPopulation |
adults with HER2-low breast cancer
ⓘ
adults with HER2-positive cancer ⓘ |
| hasTherapeuticArea | oncology ⓘ |
| isAdministeredBy | intravenous route ⓘ |
| isCoDevelopedBy | AstraZeneca ⓘ |
| isContraindicatedIn | patients with known serious hypersensitivity to trastuzumab deruxtecan components ⓘ |
| isDevelopedBy | Daiichi Sankyo ⓘ |
| isGivenInCombinationWith | premedication for infusion-related reactions in some protocols ⓘ |
| isMetabolizedTo | DXd (deruxtecan) payload ⓘ |
| isUsedFor |
treatment of HER2-expressing cancers
ⓘ
treatment of metastatic cancer ⓘ |
| mechanismOfAction |
binds HER2 on tumor cells and delivers a cytotoxic topoisomerase I inhibitor
ⓘ
induces DNA damage and apoptosis in HER2-expressing tumor cells ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
HER2
ⓘ
linked to:
HER2 receptor
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: fam-trastuzumab deruxtecan Description of subject: Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: fam-trastuzumab deruxtecan
linked to: fam-trastuzumab deruxtecan